HRT Financial’s C4 Therapeutics CCCC Stock Holding History

HRT Financial’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89K	Sell	19,200 -4,500	-19%	-$15.4K	﹤0.01%	3645
2026 Q1	$62K	Buy	+23,700	New	+$55.8K	﹤0.01%	3425

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial's CCCC Position: Q2 2026 in Review

HRT Financial sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 162,930 shares — an estimated $557K sold.

HRT Financial first reported a position in CCCC in Q2 2022 and held it in 6 quarters. The position peaked at $721K in Q2 2022. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

HRT Financial reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 162,930 C4 Therapeutics shares in Q2 2026, an estimated $557K.
HRT Financial first reported a position in C4 Therapeutics in Q2 2022 and held it in 6 quarters.
HRT Financial's C4 Therapeutics position peaked at $721K in Q2 2022.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.